ASLAN Pharmaceuticals Limited [NASDAQ: ASLN] gained 17.72% or 0.56 points to close at $3.72 with a heavy trading volume of 2328967 shares. The company report on May 25, 2021 that ASLAN Pharmaceuticals to Participate In Fireside Chat at Jefferies Virtual Healthcare Conference.
ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, announced Dr Carl Firth, Chief Executive Officer of the company, will participate in a fireside chat at the Jefferies Virtual Healthcare Conference on Tuesday, 1 June, 2021 at 11:30am ET. The conference will be held from 1-4 June 2021.
A live webcast of the chat will be available using this link: https://wsw.com/webcast/jeff174/asln/1851714 and in the Investor Relations section of ASLAN’s website at www.aslanpharma.com, with a replay available shortly after the event.
It opened the trading session at $3.19, the shares rose to $3.87 and dropped to $3.19, the range by which the price of stock traded the whole day. The daily chart for ASLN points out that the company has recorded 80.58% gains over the past six months. However, it is still -195.24% lower than its most recent low trading price.
If we look at the average trading volume of 732.88K shares, ASLN reached to a volume of 2328967 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about ASLAN Pharmaceuticals Limited [ASLN]:
H.C. Wainwright have made an estimate for ASLAN Pharmaceuticals Limited shares, keeping their opinion on the stock as Buy, with their previous recommendation back on January 14, 2019.
The Average True Range (ATR) for ASLAN Pharmaceuticals Limited is set at 0.24
Trading performance analysis for ASLN stock
ASLAN Pharmaceuticals Limited [ASLN] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 24.83. With this latest performance, ASLN shares gained by 48.80% in over the last four-week period, additionally plugging by 80.58% over the last 6 months – not to mention a rise of 101.08% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ASLN stock in for the last two-week period is set at 73.58, with the RSI for the last a single of trading hit 82.56, and the three-weeks RSI is set at 66.12 for ASLAN Pharmaceuticals Limited [ASLN]. The present Moving Average for the last 50 days of trading for this stock 3.04, while it was recorded at 3.21 for the last single week of trading, and 2.52 for the last 200 days.
ASLAN Pharmaceuticals Limited [ASLN]: A deeper dive into fundamental analysis
Return on Total Capital for ASLN is now -124.73, given the latest momentum, and Return on Invested Capital for the company is -151.34. Additionally, ASLN Total Debt to Total Capital is recorded at 224.37, with Total Debt to Total Assets ending up at 117.26.
Reflecting on the efficiency of the workforce at the company, ASLAN Pharmaceuticals Limited [ASLN] managed to generate an average of -$901,432 per employee.ASLAN Pharmaceuticals Limited’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.20 and a Current Ratio set at 3.20.
ASLAN Pharmaceuticals Limited [ASLN]: An earnings per share (EPS) analysis
With the latest financial reports released by the company, ASLAN Pharmaceuticals Limited posted -0.1/share EPS, while the average EPS was predicted by analysts to be reported at -0.08/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -25.00%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ASLN.
An analysis of insider ownership at ASLAN Pharmaceuticals Limited [ASLN]
Positions in ASLAN Pharmaceuticals Limited stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 34 institutional holders increased their position in ASLAN Pharmaceuticals Limited [NASDAQ:ASLN] by around 22,299,082 shares. Additionally, 5 investors decreased positions by around 966,792 shares, while 2 investors held positions by with 4,357,225 shares. The mentioned changes placed institutional holdings at 27,623,099 shares, according to the latest SEC report filing. ASLN stock had 29 new institutional investments in for a total of 21,573,859 shares, while 0 institutional investors sold positions of 0 shares during the same period.